60 Degrees Pharma Partners With Runway Health to Expand ARAKODA Access; Shares Rise

60 Degrees Pharma Inc. (NASDAQ: SIXT) announced a strategic partnership with Runway Health on January 22, 2026, to broaden access to its investigational drug ARAKODA for patients with advanced solid tumors. The collaboration aims to integrate ARAKODA into Runway Health’s digital health platform, enhancing patient eligibility screening and clinical trial participation. Following the announcement, 60 Degrees Pharma’s stock surged 18.7% in after-hours trading, closing at $12.45 per share. The partnership leverages Runway Health’s AI-driven oncology solutions to streamline patient identification and recruitment for ongoing Phase 2 trials of ARAKODA. The drug, an oral small molecule inhibitor targeting the PI3K pathway, has demonstrated preliminary efficacy in early-stage studies. The alliance marks a key step in 60 Degrees Pharma’s strategy to accelerate commercial readiness ahead of anticipated regulatory filings in 2027. Runway Health will provide data analytics and telehealth support to improve trial efficiency and patient outcomes.